Theracos, Inc. is a pharmaceutical research and development company which develops novel therapeutic agents for diseases with significant unmet medical need. It currently has five internal development programs underway in three therapeutic areas: metabolism, inflammation, and psychiatry. The most advanced program, entering Phase II clinical trials, is directed toward the treatment of type 2 diabetes. The company is developing a series of SGLT2 inhibitors as a potential drug to treat type 2 diabetes. It is reported that the process works by inhibiting the kidneyâs ability to recover glucose thatâs been excreted â thereby increasing the amount that is shed in urine, and decreasing the amount retained in the blood. The company is also reporte as recruiting participants with type 2 diabetes for a Phase 2b dosing trial. The firm's experimental drug - bexagliflozin - has been tested in studies in the U.S., Europe, Russia and Japan. It is reported as working in a similar manner to Farxiga, a type 2 diabetes drug developed by AstraZeneca and approved in 2014 that also works as an SGLT2 inhibitor. Other such drugs are Invokana and Jardi
